摘要
目的观察靶向治疗慢性粒细胞白血病(CML)慢性期患儿的疗效及安全性。方法选取2014年1月1日-2017年12月31日在我院血液科确诊为初发CML慢性期的患儿共5例。其中,男1例,女4例,中位年龄10(6～11)岁,均予以口服伊马替尼300mg/(m^2·d)治疗。定期观察患儿临床表现、外周血象和分子生物学指标的变化,评估疗效,同时记录治疗期间不良反应发生情况。结果5例患儿中,4例经伊马替尼规范治疗3个月后获得完全血液学反应(CHR),且在治疗12个月时均获得主要分子学反应(MMR)。1例不耐受伊马替尼,换用达沙替尼治疗1个月后获得CHR,4个月后融合基因定量检测达最佳疗效。结论伊马替尼治疗儿童CML慢性期早期疗效确切,且不良反应较轻,耐受性好,较为安全。达沙替尼可使CML患儿达到更快、更深层次的缓解,在不耐受伊马替尼的情况下,可作为二线治疗选择。
Objective To observe the efficacy and safety of targeted therapy in children with chronic myeloid leukemia(CML)in chronic phase.Methods A total of 5 children diagnosed with CML in chronic phase in the Department of Hematology in our hospital from January 1,2014 to December 31,2017 were selected.Among them,1 male and 4 female,with a median age of 10 years(6~11 years).All these patients were treated with imatinib 300mg/(m^2·d).The changes of clinical manifestations,peripheral blood and molecular biological indexes were observed regularly,and the adverse effects were evaluated.Results 4 of the 5 patients received CHR after 3 months of imatinib standard treatment,and received MMR at 12 months of treatment.1 case was imintinib intolerance,who changed to dasatinib treatment,CHR was obtained 1month later.After 4 months,the fusion gene quantitative test showed the best curative effect.Conclusions Imatinib is effective and safe in the treatment of children with CML chronic stage.Dasatinib can achieve a faster and deeper remission in children with CML,and can be selected as second-line treatment if imatinib is intolerant.
作者
李岩
郝国平
王晓欢
程艳丽
LI Yan;HAO Guoping;WANG Xiaohuan;CHENG Yanli(Department of Pediatrics,Shanxi Medical University,Taiyuan 030001,China;Department of Hematology,Shanxi Children′s Hospital,Taiyuan 030013,China)
出处
《中国小儿血液与肿瘤杂志》
CAS
2019年第1期27-31,共5页
Journal of China Pediatric Blood and Cancer
关键词
慢性粒细胞白血病
儿童
靶向治疗
疗效
安全性
Chronic myeloid leukemia
Children
Targeted therapy
Curative effect
Safety
